Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.
PR

Priya Ramanathan, PharmD

Pharmacy Columnist

Priya Ramanathan is an ambulatory-care pharmacist who has run titration clinics for incretin therapy since 2021 and has personally counselled somewhere north of nine hundred patients through a first injection.

Her column is the Journal’s bridge between the trial literature and the fifteen-minute appointment: what the label says, what the pharmacokinetics permit, and what a person will actually do on a Tuesday night with a vial, a syringe and no supervision.

She is careful to say that a column is not a consultation. She is equally careful to say that the most common preventable harm she sees is not an overdose — it is a person titrating on a fixed calendar through side effects that should have stopped the escalation two weeks earlier.

With the Journal since
February 2024
Based in
Toronto
Pieces
131

PharmD; BCACP (Board Certified Ambulatory Care Pharmacist)

Recent work

131 pieces

Explainers

Maximum tolerated is not maximum approved

Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.

Priya Ramanathan, PharmD·25 Jun 2026·7 min

Pharmacology

Diminishing returns, quantified

The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.

Priya Ramanathan, PharmD·21 Jan 2026·11 min